LON:HEMO - Hemogenyx Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 2.94 +0.09 (+3.16 %)
(As of 02/19/2019 08:03 AM ET)
Previous CloseGBX 2.85
Today's RangeGBX 2.78 - GBX 2.94
52-Week RangeGBX 2 - GBX 6.80
Volume53,996 shs
Average Volume8.01 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing CDX bi-specific antibody, an immunotherapy product for patient conditioning undergoing bone marrow/hematopoietic stem cell (BM/HSC) transplants and/or for relapsed acute myelogenous leukemia patients; and Hu-PHEC, a cell therapy product for BM/HSC transplants. The company has a research collaboration agreement with The Rockefeller University to develop treatments for autoimmune diseases. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.

Receive HEMO News and Ratings via Email

Sign-up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Hemogenyx Pharmaceuticals (LON:HEMO) Frequently Asked Questions

What is Hemogenyx Pharmaceuticals' stock symbol?

Hemogenyx Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HEMO."

Has Hemogenyx Pharmaceuticals been receiving favorable news coverage?

Press coverage about HEMO stock has trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hemogenyx Pharmaceuticals earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.

Who are some of Hemogenyx Pharmaceuticals' key competitors?

Who are Hemogenyx Pharmaceuticals' key executives?

Hemogenyx Pharmaceuticals' management team includes the folowing people:
  • Dr. Vladislav Sandler Ph.D., Co-Founder, CEO & Director
  • Ms. Alexis M. Sandler, Co-Founder, COO & Non-Exec. Director
  • Mr. Lawrence Pemble, Chief Operating Officer
  • Sir Marc Feldmann MB BS, BSc(Med) Hons, PhD, FRCPath, FRCP, FMedSci, Exec. Chairman & Chairman of Advisory Board
  • Mr. Andrew Wright, Financial Controller & Company Sec.

How do I buy shares of Hemogenyx Pharmaceuticals?

Shares of HEMO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hemogenyx Pharmaceuticals' stock price today?

One share of HEMO stock can currently be purchased for approximately GBX 2.94.

What is Hemogenyx Pharmaceuticals' official website?

The official website for Hemogenyx Pharmaceuticals is http://silverfalconplc.com/.

MarketBeat Community Rating for Hemogenyx Pharmaceuticals (LON HEMO)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Hemogenyx Pharmaceuticals and other stocks. Vote "Outperform" if you believe HEMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HEMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel